Science Advisory Board to the National Center for Toxicological Research Advisory Committee; Notice of Meeting, 62508-62509 [2016-21688]
Download as PDF
62508
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on ‘‘E17 General Principles for Planning
and Design of Multi-Regional Clinical
Trials.’’ It does not establish any rights
for any person and is not binding on
FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
II. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.regulations.gov, https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, or https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm.
Dated: September 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–21689 Filed 9–8–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Science Advisory Board to the
National Center for Toxicological
Research Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Science Advisory Board
(SAB) to the National Center for
Toxicological Research (NCTR). The
general function of the committee is to
provide advice and recommendations to
the Agency on FDA’s regulatory issues.
At least one portion of the meeting will
be closed to the public.
DATES: The meeting will be held on
November 1, 2016, from 8 a.m. to 5:30
p.m., and on November 2, 2016, from 8
a.m. to 11:40 a.m.
ADDRESSES: Crowne Plaza Hotel, 201 S.
Shackleford Rd., Little Rock, AR 72211.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Donna Mendrick, National Center for
Toxicological Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 2208, Silver Spring,
MD 20993–0002, 301–796–8892 or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On November 1, 2016, the
SAB Chair will welcome the
participants, and the NCTR Director will
provide a Center-wide update on
scientific initiatives and
accomplishments during the past year.
The SAB will be presented with an
overview of the Division of
Bioinformatics and Biostatistics
Subcommittee and the Subcommittee
Site Visit Report and a response to this
review. There will be the public
comment session and an update from
the NCTR Research Divisions.
On November 2, 2016, the Center for
Biologics and Evaluation and Research,
Center for Drug Evaluation and
Research, Center for Devices and
Radiological Health, Office of Food and
Veterinary Medicine, Center for Tobacco
Products, and the Center for Veterinary
Medicine will each briefly discuss their
center-specific research strategic needs
and potential areas of collaboration.
Following an open discussion of all
the information presented, the open
session of the meeting will close so the
SAB members can discuss personnel
issues at NCTR at the end of each day.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: On November 1, 2016,
from 8 a.m. to 5:30 p.m., and November
2, 2016, from 8 a.m. to 11:40 a.m., the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions may be made to the contact
person on or before October 25, 2016.
Oral presentations from the public will
be scheduled on November 1, 2016,
between approximately 1:15 p.m. to
2:15 p.m. Those individuals interested
in making formal oral presentations
should notify the contact person and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation on
or before October 17, 2016. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
October 18, 2016.
Closed Committee Deliberations: On
November 1, 2016, from 5:30 p.m. to 6
p.m., and November 2, 2016, from 11:40
a.m. to 12:15 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). This
portion of the meeting will be closed to
permit discussion of information
concerning individuals associated with
the research programs at NCTR.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Donna
Mendrick at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
E:\FR\FM\09SEN1.SGM
09SEN1
Federal Register / Vol. 81, No. 175 / Friday, September 9, 2016 / Notices
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–21688 Filed 9–8–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–D–2241]
Substantiation for Structure/Function
Claims Made in Infant Formula Labels
and Labeling: Draft Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a draft
guidance for industry entitled
‘‘Substantiation for Structure/Function
Claims Made in Infant Formula Labels
and Labeling.’’ The draft guidance,
when finalized, will describe the type
and quality of evidence that we
recommend that infant formula
manufacturers and distributors have to
substantiate structure/function claims in
infant formula labels and labeling. This
draft guidance is intended to help infant
formula manufacturers making
structure/function claims comply with
the statutory requirement that all claims
in infant formula labeling must be
truthful and not misleading under the
Federal Food, Drug, and Cosmetic Act
(the FD&C Act).
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that we consider
your comment on the draft guidance
before we begin work on the final
version of the guidance, submit either
electronic or written comments on the
draft guidance by November 8, 2016.
ADDRESSES: You may submit comments
as follows:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
VerDate Sep<11>2014
17:11 Sep 08, 2016
Jkt 238001
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–D–2241 for ‘‘Substantiation for
Structure/Function Claims Made in
Infant Formula Labels and Labeling.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
62509
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for single
copies of the draft guidance to the Office
of Nutrition and Food Labeling, Center
for Food Safety and Applied Nutrition
(HFS–800), Food and Drug
Administration, 5001 Campus Dr.,
College Park, MD 20740. Send two selfaddressed adhesive labels to assist that
office in processing your request. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance.
FOR FURTHER INFORMATION CONTACT:
With regard to this draft guidance:
Gillian Robert-Baldo, Center for Food
Safety and Applied Nutrition (HFS–
850), Food and Drug Administration,
5001 Campus Dr., College Park, MD
20740, 240–402–1451.
With regard to the information
collection issues: Domini Bean, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400T, Rockville, MD 20850,
domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
We are announcing the availability of
a draft guidance for industry entitled
‘‘Substantiation for Structure/Function
Claims Made in Infant Formula Labels
and Labeling.’’ We are issuing this draft
guidance consistent with our good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, will represent our current
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 81, Number 175 (Friday, September 9, 2016)]
[Notices]
[Pages 62508-62509]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21688]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
Science Advisory Board to the National Center for Toxicological
Research Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Science Advisory Board (SAB)
to the National Center for Toxicological Research (NCTR). The general
function of the committee is to provide advice and recommendations to
the Agency on FDA's regulatory issues. At least one portion of the
meeting will be closed to the public.
DATES: The meeting will be held on November 1, 2016, from 8 a.m. to
5:30 p.m., and on November 2, 2016, from 8 a.m. to 11:40 a.m.
ADDRESSES: Crowne Plaza Hotel, 201 S. Shackleford Rd., Little Rock, AR
72211. Answers to commonly asked questions including information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: Donna Mendrick, National Center for
Toxicological Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-
796-8892 or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area). A notice in the Federal
Register about last minute modifications that impact a previously
announced advisory committee meeting cannot always be published quickly
enough to provide timely notice. Therefore, you should always check the
Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm
and scroll down to the appropriate advisory committee meeting link, or
call the advisory committee information line to learn about possible
modifications before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On November 1, 2016, the SAB Chair will welcome the
participants, and the NCTR Director will provide a Center-wide update
on scientific initiatives and accomplishments during the past year. The
SAB will be presented with an overview of the Division of
Bioinformatics and Biostatistics Subcommittee and the Subcommittee Site
Visit Report and a response to this review. There will be the public
comment session and an update from the NCTR Research Divisions.
On November 2, 2016, the Center for Biologics and Evaluation and
Research, Center for Drug Evaluation and Research, Center for Devices
and Radiological Health, Office of Food and Veterinary Medicine, Center
for Tobacco Products, and the Center for Veterinary Medicine will each
briefly discuss their center-specific research strategic needs and
potential areas of collaboration.
Following an open discussion of all the information presented, the
open session of the meeting will close so the SAB members can discuss
personnel issues at NCTR at the end of each day.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: On November 1, 2016, from 8 a.m. to 5:30 p.m., and
November 2, 2016, from 8 a.m. to 11:40 a.m., the meeting is open to the
public. Interested persons may present data, information, or views,
orally or in writing, on issues pending before the committee. Written
submissions may be made to the contact person on or before October 25,
2016. Oral presentations from the public will be scheduled on November
1, 2016, between approximately 1:15 p.m. to 2:15 p.m. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before October 17, 2016.
Time allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by October 18, 2016.
Closed Committee Deliberations: On November 1, 2016, from 5:30 p.m.
to 6 p.m., and November 2, 2016, from 11:40 a.m. to 12:15 p.m., the
meeting will be closed to permit discussion where disclosure would
constitute a clearly unwarranted invasion of personal privacy (5 U.S.C.
552b(c)(6)). This portion of the meeting will be closed to permit
discussion of information concerning individuals associated with the
research programs at NCTR.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Donna Mendrick at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on
[[Page 62509]]
public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: September 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-21688 Filed 9-8-16; 8:45 am]
BILLING CODE 4164-01-P